Innate Pharma SA (FRA:IDD)
€ 1.614 0.01 (0.62%) Market Cap: 136.32 Mil Enterprise Value: 80.03 Mil PE Ratio: 0 PB Ratio: 4.66 GF Score: 67/100

Q2 2022 Innate Pharma SA Earnings Call Transcript

Sep 15, 2022 / 12:00PM GMT
Release Date Price: €2.55 (-1.77%)
Operator

(technical difficulty) And Communications. Mr. Wheeler, you may begin your conference.

Henry Wheeler
Innate Pharma S.A. - VP & Head of IR

Thank you very much. Good morning and good afternoon, and welcome, everybody. This morning, Innate issued a press release providing a business update for the half year '22 results. We look forward to highlighting the progress made during the quarter as well as addressing future goals and milestones. The press release and today's presentation are both available on the IR section of the website.

Please turn to Slide #2. Before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook and additional -- in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ as forecasted. Turning to Slide 3. On today's call, we will be joined by Mondher Mahjoubi, our CEO, who will then hand over to Joyson Karakunnel, EVP and Chief Medical Officer; Yannis Morel, EVP of Business

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot